Group 1 - Daxing District is committed to developing the biopharmaceutical industry as a core track for high-quality development, aiming to enhance its international competitiveness in the cell and gene therapy (CGT) field [1][2] - The OpenCGT platform, launched by Jitai Technology, focuses on addressing industry pain points in precise drug delivery, reducing development barriers and costs, and facilitating the research and clinical transformation of breakthrough CGT therapies [1][2] - Jitai Technology has completed a Series D financing round, raising a total of 400 million RMB, which will accelerate the advancement of multiple strategic priorities, including platform automation upgrades and international strategic cooperation [2][3] Group 2 - The Beijing Municipal Science and Technology Commission and other departments have announced a three-year action plan to accelerate innovation in the CGT industry, aiming to cultivate over 20 leading technology companies in the field by 2027 [2] - The Beijing Pharmaceutical Health Industry Investment Fund, established by the Beijing government, focuses on investing in innovative drugs, medical devices, and emerging industries such as CGT and digital healthcare [3] - The OpenCGT platform fills a critical gap in the transformation of high-end formulations and delivery systems, significantly contributing to Beijing's goal of becoming an international innovation hub for the CGT industry [3]

Group 1 - JiTai Technology has completed a Series D financing round, raising a total of 400 million RMB, led by the Beijing Medical Health Industry Investment Fund and the Daxing District Industrial Investment Fund [1] - The funds will be used to advance multiple strategic priorities, including platform automation upgrades, self-developed product pipeline advancement, deepening international strategic cooperation, and attracting high-end talent [1] - The cell and gene therapy (CGT) sector is identified as a key area for drug innovation, following small molecule drugs and antibody drugs [1] Group 2 - In 2024, Beijing's Science and Technology Commission and other departments will release a three-year action plan to accelerate innovation in the CGT industry, aiming to cultivate over 20 leading CGT technology companies by 2027 [1] - JiTai Technology has established the Open CGT technology platform, focusing on addressing industry pain points in precise drug delivery, reducing development barriers and costs, and facilitating the research and clinical transformation of breakthrough CGT therapies [1] - The Open CGT platform aims to connect research capabilities from top universities, resources from major hospitals, and the full R&D chain of CGT innovative pharmaceutical companies, with its first project already launched [1]

Core Viewpoint - JiTai Technology, a leading AI-driven nanomedicine company, has completed a Series D financing round of 400 million RMB, aimed at accelerating its strategic initiatives in platform automation, product pipeline development, international collaboration, and talent acquisition [2][6]. Financing and Investment - The recent financing round was led by the Beijing Pharmaceutical and Health Industry Investment Fund and the Daxing District Industrial Investment Fund, contributing to a total funding exceeding 2 billion RMB (approximately 300 million USD) since the company's inception [2][6]. - JiTai Technology previously completed two financing rounds in February 2022, raising a total of 150 million USD, and a Series C round in June 2024, raising 100 million USD [5][6]. Company Overview - Founded in 2020, JiTai Technology focuses on AI-driven innovations in nanomaterials, specifically targeting drug delivery and discovery technologies to combat diseases and aging [3]. - The company was co-founded by prominent scientists, including Dr. Chen Hongmin and Dr. Lai Caida, and has developed three core AI platforms: AiLNP, AiRNA, and AiTEM [3]. Industry Position and Collaboration - JiTai Technology is recognized as one of the "Four Little Dragons" in AI pharmaceuticals, alongside Deep Intelligence, Crystal Technology, and InSilico Medicine, emphasizing a collaborative rather than competitive approach within the industry [4]. - The company has achieved breakthroughs in targeted delivery capabilities for key organs and cells, providing opportunities for treating various diseases, including tumors and neurodegenerative disorders [4]. Strategic Initiatives - The company has launched the Open CGT technology platform, which aims to address industry challenges in precise drug delivery and facilitate the development of breakthrough cell and gene therapies [6][7]. - The first project under this platform focuses on enabling Rui Zheng Gene to develop mRNA-LNP-based liver-targeted CRISPR gene editing therapies [7]. Future Outlook - JiTai Technology's CEO highlighted that cell and gene therapy (CGT) will be a pillar of China's biopharmaceutical industry, representing the next generation of drug development [8]. - The company aims to contribute significantly to the entire drug delivery process, facilitating the transition from early-stage pipelines to market-ready products [8].